Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle of the week is already here, which means there is much to do. No doubt, you can relate on some level. So please join us as we grab a cup of stimulation — remember, no prescription is required — and tackle the Zoom calls and deadlines that are piling up. Meanwhile, here is the latest grab of items of interest to help you along. Hope you conquer the world today, and do stay in touch. …

The Trump administration is accelerating a plan to begin offering coronavirus shots in pharmacies — a move that comes after federal officials faced fierce criticism for the slow pace of immunizations, Politico says. Within the next two weeks, Operation Warp Speed estimates 3,000 to 6,000 pharmacies could begin administering Covid-19 shots. The administration announced in November that it would work with major pharmacy chains and independent community pharmacies to distribute vaccines but did not lay out a timetable.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.